Nanobiotix Shares Surge 10%: Stifel Targets 45 Euros for Purchase
The trading session on Friday, March 13, is marked by high activity on NANOBIOTIX, with the stock up 10.02% at €30.20 during the session, on volumes more than three times their usual average. This rebound follows a closing down 5.34% the previous day, itself following a drop of more than 10% recorded on March 11. Over the past month, the stock has gained more than 27%, and nearly 55% over three months.
Market Dynamics and Technical Indicators
A simultaneous reading of the available indicators reveals a unique configuration: the intraday variation exceeds the 5% alert threshold in both directions over the last two sessions, while the volumes traded this Friday exceed three times the reference average—a threshold rarely crossed. Far from contradicting each other, these signals paint a coherent picture: a stock under strong speculative pressure, traversed by powerful and contradictory short-term directional flows, but supported by a clearly upward monthly dynamic. Technically, the price moves during the session above the 50-day moving average (€21.16) and approaches the resistance identified at €33.50, with an RSI at 64—retreating from the recently approached overbought zone—indicating a correction of tension without breaking the underlying trend. The MACD, positive at 0.31, confirms that the medium-term bullish momentum remains intact despite the recent session's turmoil.
Analyst Positions and Market Context
The day is also marked by a significant positioning from analysts. Stifel initiated a buy recommendation on the stock this Friday, coupled with a target price increase from €23.00 to €45.00, representing a potential progression of about 49% compared to the current price. The day before, Kempen maintained its buy recommendation while revising its target from €22.00 to €27.00. These two analyst revisions occur in a context of a generally stable market, with the CAC 40 losing 0.07% during the session this Friday. The divergence between the two target objectives—€27.00 for Kempen versus €45.00 for Stifel—illustrates the uncertainty that still surrounds the valuation of a stock whose price has increased more than tenfold in a year.
